250 related articles for article (PubMed ID: 24848755)
1. Tofogliflozin: first global approval.
Poole RM; Prossler JE
Drugs; 2014 Jun; 74(8):939-44. PubMed ID: 24848755
[TBL] [Abstract][Full Text] [Related]
2. Ipragliflozin: first global approval.
Poole RM; Dungo RT
Drugs; 2014 Apr; 74(5):611-7. PubMed ID: 24668021
[TBL] [Abstract][Full Text] [Related]
3. Luseogliflozin: first global approval.
Markham A; Elkinson S
Drugs; 2014 Jun; 74(8):945-50. PubMed ID: 24848756
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study.
Kaku K; Watada H; Iwamoto Y; Utsunomiya K; Terauchi Y; Tobe K; Tanizawa Y; Araki E; Ueda M; Suganami H; Watanabe D;
Cardiovasc Diabetol; 2014 Mar; 13():65. PubMed ID: 24678906
[TBL] [Abstract][Full Text] [Related]
5. Tofogliflozin: a highly selective SGLT2 inhibitor for the treatment of type 2 diabetes.
Rosenwasser RF; Rosenwasser JN; Sutton D; Choksi R; Epstein B
Drugs Today (Barc); 2014 Nov; 50(11):739-45. PubMed ID: 25525634
[TBL] [Abstract][Full Text] [Related]
6. [The SGLT2 inhibitor empagliflozin: results of EMPA-REG OUTCOMER trial].
Okamura T; Koiwai K
Nihon Yakurigaku Zasshi; 2016; 148(5):282. PubMed ID: 27803444
[No Abstract] [Full Text] [Related]
7. Efficacy and Safety of Tofogliflozin on 24-h Glucose Profile Based on Continuous Glucose Monitoring: Crossover Study of Sodium-Glucose Cotransporter 2 Inhibitor.
Kurozumi A; Okada Y; Shimokawa M; Goshima Y; Otsuka T; Narisawa M; Torimoto K; Tanaka Y
Diabetes Technol Ther; 2019 Jul; 21(7):385-392. PubMed ID: 31210529
[No Abstract] [Full Text] [Related]
8. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.
Nagata T; Fukuzawa T; Takeda M; Fukazawa M; Mori T; Nihei T; Honda K; Suzuki Y; Kawabe Y
Br J Pharmacol; 2013 Oct; 170(3):519-31. PubMed ID: 23751087
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and Pharmacodynamics of Tofogliflozin (a Selective SGLT2 Inhibitor) in Healthy Male Subjects.
Kasahara-Ito N; Fukase H; Ogama Y; Saito T; Ohba Y; Shimada S; Takano Y; Ichihara T; Terao K; Nakamichi N; Kumagai Y; Ikeda S
Drug Res (Stuttg); 2017 Jun; 67(6):349-357. PubMed ID: 28427104
[TBL] [Abstract][Full Text] [Related]
10. [Contributions of SGLT-2 and new drugs under investigation].
Mediavilla Bravo JJ
Semergen; 2014 Jul; 40 Suppl 2():34-40. PubMed ID: 25311718
[TBL] [Abstract][Full Text] [Related]
11. A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.
Kasahara N; Fukase H; Ohba Y; Saito T; Miyata K; Iida S; Takano Y; Ikeda S; Harigai M; Terao K
Drug Res (Stuttg); 2016 Feb; 66(2):74-81. PubMed ID: 26158794
[TBL] [Abstract][Full Text] [Related]
12. Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.
Bekki M; Tahara N; Tahara A; Igata S; Honda A; Sugiyama Y; Nakamura T; Sun J; Kumashiro Y; Matsui T; Fukumoto Y; Yamagishi SI
Curr Vasc Pharmacol; 2019; 17(4):411-420. PubMed ID: 29766812
[TBL] [Abstract][Full Text] [Related]
13. Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A subanalysis of a post-marketing study (J-STEP/EL Study).
Kaku K; Naito Y; Senda M; Kurihara Y; Gunji R; Kakiuchi S; Utsunomiya K
J Diabetes Investig; 2020 Mar; 11(2):405-416. PubMed ID: 31390166
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial.
Terauchi Y; Tamura M; Senda M; Gunji R; Kaku K
Diabetes Obes Metab; 2017 Oct; 19(10):1397-1407. PubMed ID: 28371205
[TBL] [Abstract][Full Text] [Related]
15. Clinical implication of SGLT2 inhibitors in type 2 diabetes.
Kim GW; Chung SH
Arch Pharm Res; 2014 Aug; 37(8):957-66. PubMed ID: 24950857
[TBL] [Abstract][Full Text] [Related]
16. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
Nagata T; Fukazawa M; Honda K; Yata T; Kawai M; Yamane M; Murao N; Yamaguchi K; Kato M; Mitsui T; Suzuki Y; Ikeda S; Kawabe Y
Am J Physiol Endocrinol Metab; 2013 Feb; 304(4):E414-23. PubMed ID: 23249697
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
18. Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Tofogliflozin (A SELECTIVE SGLT2 Inhibitor) in Patients with Type 2 Diabetes Mellitus.
Ikeda S; Takano Y; Schwab D; Portron A; Kasahara-Ito N; Saito T; Iida S
Drug Res (Stuttg); 2019 Jun; 69(6):314-322. PubMed ID: 30103216
[TBL] [Abstract][Full Text] [Related]
19. Molecule of the month. Dapagliflozin.
Drug News Perspect; 2007 Dec; 20(10):645. PubMed ID: 18301798
[No Abstract] [Full Text] [Related]
20. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Davidson JA; Kuritzky L
Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]